Tumor heterogenicity: multiple needle biopsies from different lesion sites—key to successful targeted therapy and immunotherapy
- 1 February 2018
- journal article
- editorial
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 7 (S1) , S46-S48
Abstract
Tumor heterogenicity: multiple needle biopsies from different lesion sites—key to successful targeted therapy and immunotherapyKeywords
This publication has 20 references indexed in Scilit:
- Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand–1 Expression for Immunotherapy in Non–Small Cell Lung CancerRadiology, 2018
- Blood-based biomarkers in lung cancer: prognosis and treatment decisionsTranslational Lung Cancer Research, 2017
- Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomicsClinical Proteomics, 2017
- Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case seriesRespiratory Medicine Case Reports, 2017
- Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatmentRespiratory Medicine Case Reports, 2017
- Effectiveness of the Benign and Malignant Diagnosis of Mediastinal and Hilar Lymph Nodes by Endobronchial Ultrasound ElastographyJournal of Cancer, 2017
- Multiple guided technologies based on radial probe endobronchial ultrasound for the diagnosis of solitary peripheral pulmonary lesions: a single-center studyJournal of Cancer, 2017
- Radial Endobronchial Ultrasound (EBUS) Guided Suction Catheter-Biopsy in Histological Diagnosis of Peripheral Pulmonary LesionsJournal of Cancer, 2016
- Efficient utilization of EBUS-TBNA samples for both diagnosis and molecular analysesOncoTargets and Therapy, 2014
- Pharmacogenomic biomarkers for personalized cancer treatmentJournal of Internal Medicine, 2014